KR102793666B1 - 퓨리논 화합물 및 암 치료에서의 이의 용도 - Google Patents

퓨리논 화합물 및 암 치료에서의 이의 용도 Download PDF

Info

Publication number
KR102793666B1
KR102793666B1 KR1020207037917A KR20207037917A KR102793666B1 KR 102793666 B1 KR102793666 B1 KR 102793666B1 KR 1020207037917 A KR1020207037917 A KR 1020207037917A KR 20207037917 A KR20207037917 A KR 20207037917A KR 102793666 B1 KR102793666 B1 KR 102793666B1
Authority
KR
South Korea
Prior art keywords
methyl
amino
purin
dihydro
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207037917A
Other languages
English (en)
Korean (ko)
Other versions
KR20210020944A (ko
Inventor
모리스 레이몬드 버쇼일 핀레이
프레데릭 울프 골드버그
마틴 리처드 하워드
아틸라 쿠안 츠에이 팅
Original Assignee
아스트라제네카 아베
캔써 리서치 테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베, 캔써 리서치 테크놀로지 리미티드 filed Critical 아스트라제네카 아베
Publication of KR20210020944A publication Critical patent/KR20210020944A/ko
Application granted granted Critical
Publication of KR102793666B1 publication Critical patent/KR102793666B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Measurement Of Radiation (AREA)
KR1020207037917A 2018-06-15 2019-06-14 퓨리논 화합물 및 암 치료에서의 이의 용도 Active KR102793666B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685325P 2018-06-15 2018-06-15
US62/685,325 2018-06-15
PCT/EP2019/065686 WO2019238929A1 (en) 2018-06-15 2019-06-14 Purinone compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
KR20210020944A KR20210020944A (ko) 2021-02-24
KR102793666B1 true KR102793666B1 (ko) 2025-04-08

Family

ID=67107385

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207037917A Active KR102793666B1 (ko) 2018-06-15 2019-06-14 퓨리논 화합물 및 암 치료에서의 이의 용도

Country Status (29)

Country Link
US (2) US11884671B2 (https=)
EP (1) EP3807278B1 (https=)
JP (1) JP7472044B2 (https=)
KR (1) KR102793666B1 (https=)
CN (1) CN112236431B (https=)
AR (1) AR114971A1 (https=)
AU (1) AU2019287295B2 (https=)
BR (1) BR112020025127A2 (https=)
CA (1) CA3102195A1 (https=)
CL (1) CL2020003131A1 (https=)
CO (1) CO2020015758A2 (https=)
CR (1) CR20200620A (https=)
DO (1) DOP2020000241A (https=)
EA (1) EA202190006A1 (https=)
EC (1) ECSP20080276A (https=)
ES (1) ES2931448T3 (https=)
IL (1) IL279370B2 (https=)
JO (1) JOP20200315B1 (https=)
MA (1) MA52886A (https=)
MX (1) MX2020013570A (https=)
NI (1) NI202000099A (https=)
PE (1) PE20210003A1 (https=)
PH (1) PH12020552148A1 (https=)
SG (1) SG11202012035WA (https=)
TW (1) TWI820146B (https=)
UA (1) UA126837C2 (https=)
UY (1) UY38263A (https=)
WO (1) WO2019238929A1 (https=)
ZA (1) ZA202100195B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI899080B (zh) * 2019-05-27 2025-10-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑
TWI807228B (zh) * 2019-11-25 2023-07-01 大陸商南京明德新藥研發有限公司 作為dna-pk抑制劑的嘧啶并吡咯類化合物
CN113121538B (zh) * 2019-12-31 2023-04-21 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
CN113121574B (zh) * 2019-12-31 2023-02-17 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的用途
WO2021136461A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
TWI765640B (zh) * 2020-04-10 2022-05-21 大陸商南京明德新藥研發有限公司 作為dna-pk抑制劑的氨基嘧啶化合物及其衍生物
AU2021256235B2 (en) * 2020-04-17 2024-05-09 Kangbaida (Sichuan) Biotechnology Co., Ltd. Imidazolidinone derivatives and medical use thereof
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
WO2022017368A1 (zh) * 2020-07-20 2022-01-27 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
AU2021346954A1 (en) * 2020-09-24 2023-05-25 Auckland Uniservices Limited Novel aminopyridines and their use in treating cancer
CN114573605A (zh) * 2020-12-01 2022-06-03 武汉光谷亚太医药研究院有限公司 Dna依赖蛋白激酶抑制剂及其应用
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
WO2022135555A1 (zh) * 2020-12-24 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
CN116917288B (zh) * 2021-03-22 2026-04-14 成都赜灵生物医药科技股份有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
CN117377676B (zh) * 2021-06-29 2026-04-07 康百达（四川）生物医药科技有限公司 嘌呤衍生物的晶型及其药物组合物
CN117940437A (zh) * 2021-09-07 2024-04-26 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2025199376A1 (en) * 2024-03-22 2025-09-25 Padarn Therapeutics, Inc. Cdk2 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009024824A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8591943B2 (en) * 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
ES2629006T3 (es) * 2009-10-29 2017-08-07 Vectura Limited Derivados que contienen N-heteroarilo como inhibidores de la quinasa jak3
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
SG10201601909TA (en) * 2011-03-11 2016-04-28 Gilead Calistoga Llc Combination Therapies For Hematologic Malignancies
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
JP6883653B2 (ja) * 2016-12-20 2021-06-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009024824A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders

Also Published As

Publication number Publication date
IL279370B2 (en) 2024-11-01
JP7472044B2 (ja) 2024-04-22
CO2020015758A2 (es) 2021-04-30
NI202000099A (es) 2021-09-24
JOP20200315B1 (ar) 2024-04-18
IL279370A (en) 2021-01-31
PE20210003A1 (es) 2021-01-05
SG11202012035WA (en) 2021-01-28
WO2019238929A1 (en) 2019-12-19
ZA202100195B (en) 2022-08-31
CA3102195A1 (en) 2019-12-19
AU2019287295A1 (en) 2021-02-04
US11884671B2 (en) 2024-01-30
JP2021527095A (ja) 2021-10-11
EA202190006A1 (ru) 2021-03-29
MA52886A (fr) 2021-04-21
TW202035410A (zh) 2020-10-01
UA126837C2 (uk) 2023-02-08
EP3807278A1 (en) 2021-04-21
ES2931448T3 (es) 2022-12-29
IL279370B1 (en) 2024-07-01
CL2020003131A1 (es) 2021-04-30
MX2020013570A (es) 2021-05-27
US20240150355A1 (en) 2024-05-09
TWI820146B (zh) 2023-11-01
KR20210020944A (ko) 2021-02-24
US20210171525A1 (en) 2021-06-10
PH12020552148A1 (en) 2021-07-05
ECSP20080276A (es) 2021-01-29
EP3807278B1 (en) 2022-08-31
DOP2020000241A (es) 2021-04-30
UY38263A (es) 2019-12-31
CN112236431A (zh) 2021-01-15
CN112236431B (zh) 2024-02-13
BR112020025127A2 (pt) 2021-03-23
AU2019287295B2 (en) 2022-05-26
JOP20200315A1 (ar) 2020-12-07
NZ771886A (en) 2024-07-26
CR20200620A (es) 2021-03-09
AR114971A1 (es) 2020-11-11

Similar Documents

Publication Publication Date Title
KR102793666B1 (ko) 퓨리논 화합물 및 암 치료에서의 이의 용도
CA3046339C (en) Amino-triazolopyridine compounds and their use in treating cancer
KR20210146984A (ko) 에스트로겐 수용체 분해 protac
US20250136586A1 (en) Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors
EA043669B1 (ru) Пуриноновые соединения и их применение при лечении рака
HK40051945B (en) Purinone derivatives and their use in treating cancer
HK40051945A (en) Purinone derivatives and their use in treating cancer
KR20250100670A (ko) 융합 바이사이클릭 화합물 및 이의 Mer 및 Axl 억제제로서의 용도
HK40017076A (en) Amino-triazolopyridine compounds and their use in treating cancer
HK40017076B (en) Amino-triazolopyridine compounds and their use in treating cancer
HK40013563B (en) Amino-triazolopyridine compounds and their use in treating cancer
HK40013563A (en) Amino-triazolopyridine compounds and their use in treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201230

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220608

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240318

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250108

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250404

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250404

End annual number: 3

Start annual number: 1

PG1601 Publication of registration